Cart
sales@molnova.com
BILH-434
CAS No. 760169-28-6
BILH-434( BILH434 )
Catalog No. M15887 CAS No. 760169-28-6
BILH-434 is a potent HPV11 E1/E2/DNA complex inhibitor that binds to the transactivation domain (TAD) of E2 protein with a Kd of 40 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBILH-434
-
NoteResearch use only, not for human use.
-
Brief DescriptionBILH-434 is a potent HPV11 E1/E2/DNA complex inhibitor that binds to the transactivation domain (TAD) of E2 protein with a Kd of 40 nM.
-
DescriptionBILH-434 is a potent HPV11 E1/E2/DNA complex inhibitor that binds to the transactivation domain (TAD) of E2 protein with a Kd of 40 nM, has an IC50 of 180 nM in the E1-E2-ori complex formation assay.
-
In Vitro——
-
In Vivo——
-
SynonymsBILH434
-
PathwayMicrobiology/Virology
-
TargetHPV
-
RecptorHPV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number760169-28-6
-
Formula Weight608.446
-
Molecular FormulaC29H19Cl2N3O6S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name(2R,3'R,4'S,5'R)-5'-(3,4-dichlorophenyl)-5-methyl-1,3-dioxo-4'-[[4-(thiadiazol-4-yl)phenyl]carbamoyl]spiro[indene-2,2'-oxolane]-3'-carboxylic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Arkin MR, et al. Chem Biol. 2014 Sep 18;21(9):1102-14.
2. Wang Y, et al. J Biol Chem. 2004 Feb 20;279(8):6976-85.
molnova catalog
related products
-
HPV16-E711-20 epitop...
HPV16-E711-20 epitope is a well-known HLA-A*0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2 in vitro.
-
BILH-434
BILH-434 is a potent HPV11 E1/E2/DNA complex inhibitor that binds to the transactivation domain (TAD) of E2 protein with a Kd of 40 nM.
-
HPV16 E7 (86-93)
This is amino acids 86 to 93 fragment of the human papilloma virus (HPV) type 16 oncoprotein E7. This HPV16-encoded peptide has very high affinity of binding to the HLA-A*0201 molecule.This immunogenic fragment may be used in vaccines for the prevention and treatment of cervical carcinoma.
